VectorY (Group)

https://www.vectorytx.com

LinkedIn: https://www.linkedin.com/company/vectorytx1

VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for muscular and neurodegenerative diseases with high unmet medical need. Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody-based targeted degradation technologies, and proprietary manufacturing technology. VectorY develops proprietary & partnered programs and product candidates are based on new technologies that will enable the next generation of highly scalable manufacturing processes within VectorY’s own manufacturing facilities. VectorY’s manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply. *

	Start	2020-08-01 established
	Industry	gene therapy
	Industry 2	therapeutic antibody
	Person	van Deventer, Sander (VectorY 202211– CEO + Co-Founder before CTO also Co-Founder of Forbion)
	Person 2	Ritsou, Elena (VectorY 202211– COO + BioGeneration Ventures 202211– Venture Partner before GammaDelta Tx + Ipsen)

	Region	Amsterdam
	Country	Netherlands
	Street	408 Matrix Innovation Center Science Park
	City	1098 XH Amsterdam
	Tel	+31-20-226-8020
		Address record changed: 2021-06-16

Basic data	Employees	n. a.

		* Document for »About Section«: Forbion Capital Partners. (2/10/21). "Press Release: Launch of Novel Gene Therapy Company, VectorY, to Develop Innovative Vectorized Antibodies". Amsterdam.

		Record changed: 2024-06-07